The modulatory effect of lithium on doxorubicin-induced cardiotoxicity in rat

European Journal of Pharmacology

Volumn 641, Issue 2-3, 2010, Pages 193-198

  Rahimi Balaei, Maryam ^a   Momeny, Majid ^b   Babaeikelishomi, Rohollah ^c   Ejtemaei Mehr, Shahram ^a   Tavangar, Seyed Mohammad ^b   Dehpour, Ahmad Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

(Rat); Cardiotoxicity; Doxorubicin; Lithium

Indexed keywords

DOXORUBICIN; LITHIUM CHLORIDE; TROPONIN T;

ALOPECIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CACHEXIA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DISEASE MARKER; DRUG INDUCED DISEASE; EDEMA; ELECTROCARDIOGRAPHY; HEART INJURY; HEART MUSCLE CONTRACTILE FORCE; HEART PAPILLARY MUSCLE; HEART PROTECTION; HEART WEIGHT; HISTOPATHOLOGY; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; RISK REDUCTION; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOTONIC AGENTS; DOXORUBICIN; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; HEART; HEART DISEASES; LITHIUM COMPOUNDS; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; PAPILLARY MUSCLES; RANDOM ALLOCATION; RATS; RATS, WISTAR; TROPONIN T;

EID: 77954052765     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.05.046     Document Type: Article

References (52)

1. Arai M., Tomaru K., Takizawa T., Sekiguchi K., Yokoyama T., Suzuki T., Nagai R. Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. J. Mol. Cell Cardiol. 1998, 30:243-254.
2. Avissar S., Nechamkin Y., Barki-Harrington L., Roitman G., Schreiber G. Differential G protein measures in mononuclear leukocytes of patients with bipolar mood disorder are state dependent. J. Affect. Disord. 1997, 43:85-93.
3. Berridge M.J., Irvine R.F. Inositol phosphates and cell signaling. Nature 1989, 341:197-205.
4. Billingham M.E., Mason J.W., Bristow M.R., Daniels J.R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep. 1978, 62:865-872.
5. Bleuel H., Deschl U., Bertsch T., Bolz G., Rebel W. Diagnostic efficiency of troponin T measurements in rats with experimental myocardial cell damage. Exp. Toxicol. Pathol. 1995, 47:121-127.
6. Boucek J.R.J., Dodd D.A., Atkinson J.B., Oquist N., Olson R.D. Contractile failure in chronic doxorubicin-induced cardiomyopathy. J. Mol. Cell Cardiol. 1997, 29:2631-2640.
7. Boucek J.R.J., Miracle A., Anderson M., Engelman R., Atkinson J., Dodd D.A. Persistent effects of doxorubicin on cardiac gene expression. J. Mol. Cell Cardiol. 1999, 31:1435-1446.
8. Cade J.F. Lithium salts in the treatment of psychotic excitement. Aust. N. Z. J. Psychiatry 1982, 16:129-133.
9. Chuang D.M., Chen R.W., Chalecka-Franaszek E., Ren M., Hashimoto R., Senatorov V., Kanai H., Hough C., Hiroi T., Leeds P. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord. 2002, 4:129-136.
10. Cimarosti H., Rodnight R., Tavares A., Paiva R., Valentim L., Rocha E., Salbego C. An investigation of the neuroprotective effect of lithium in organotypic slice cultures of rat hippocampus exposed to oxygen and glucose deprivation. Neurosci. Lett. 2001, 315:33-36.
11. Danesi R., Del Tacca M., Soldani G. Measurement of the SaT segment as the most reliable electrocardiogram parameter for the assessment of adriamycin-induced cardiotoxicity in the rat. J. Pharmacol. Methods. 1986, 16:251-259.
12. Doroshow J.H. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 1983, 43:460-472.
13. Faghihi M., Mirershadi F., Dehpour A.R., Bazargan M. Preconditioning with acute and chronic lithium administration reduces ischemia/reperfusion injury mediated by cyclooxygenase not nitric oxide synthase pathway in isolated rat heart. Eur. J. Pharmacol. 2008, 597:57-63.
14. Fajardo G., Zhao M., Powers J., Bernstein D. Differential cardiotoxic/cardioprotective effects of ß-adrenergic receptor subtypes in myocytes and fibroblasts in doxorubicin cardiomyopathy. J. Mol. Cell Cardiol. 2006, 40:375-383.
15. Fink F.M., Genser N., Fink C., Falk M., Mair J., Maurer-Dengg K., Hammerer I., Puschendorf B. Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med. Pediatr. Oncol. 1995, 25:185-189.
16. Fisher P.W., Salloum F., Das A., Hyder H., Kukreja R.C. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Am. Heart Assoc. 2005, 111:1601-1610.
17. Fu P., Arcasoy M.O. Erythropoietin protects cardiac myocytes against anthracyclineinduced apoptosis. Biochem. Biophys. Res. Commun. 2007, 354:372-378.
18. Harvey B.H., Carstens M.E., Taljaard J.J.F. Evidence that lithium induces a glutamatergic: nitric oxide-mediated response in rat brain. Neurochem. Res. 1994, 19:469-474.
19. Hashimoto R., Nakazawa T., Yamamoto T., Chuang D.M. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J. Neurochem. 2002, 80:589-599.
20. Herman E.H., Ferrans V.J. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine. Lab. Invest. 1983, 49:69-77.
21. Herman E.H., Ferrans V.J. Animal models of anthracycline cardiotoxicity: basic mechanisms and cardioprotective activity. Prog. Pediatr. Cardiol. 1998, 8:49-58.
22. Herman E.H., El-Hage A.N., Ferrans V., Ardalan B. Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats. Toxicol. Appl. Pharmacol. 1985, 78:202-214.
23. Herman E.H., Ferrans V.J., Young R.S.K., Hamlin R.L. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs. Cancer Res. 1988, 48:6918-6925.
24. Herman E.H., Zhang J., Rifai N., Lipshultz S.E., Hasinoff B.B., Chadwick D.P., Knapton A., Chai J., Ferrans V.J. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin-and mitoxantrone-induced cardiotoxicity. Cancer Chemother. Pharmacol. 2001, 48:297-304.
25. Jaenke R.S. An anthracycline antibiotic-induced cardiomyopathy in rabbits. Lab. Invest. 1974, 30:292-304.
26. Jensen R.A. Doxorubicin cardiotoxicity: contractile changes after long-term treatment in the rat. J. Pharmacol. Exp. Ther. 1986, 236:197-203.
27. Jope R.S. A bimodal model of the mechanism of action of lithium. Mol. Psychiatry 1999, 4:21-25.
28. Jope R.S., Williams M.B. Lithium and brain signal transduction systems. Biochem. Pharmacol. 1994, 47:429-442.
29. Kalivendi S.V., Kotamaraju S., Zhao H., Joseph J., Kalyanaraman B. Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase effect of anti-apoptotic antioxidants and calcium. J. Biol. Chem. 2001, 276:47266-47276.
30. Katona C.L.E. Lithium augmentation in refractory depression. Psychiatr. Dev. 1988, 2:153-171.
31. Katus H.A., Remppis A., Neumann F.J., Scheffold T., Diederich K.W., Vinar G., Noe A., Matern G., Kuebler W. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation 1991, 83:902-912.
32. Kelishomi R.B., Ejtemaeemehr S., Tavangar S.M., Rahimian R., Mobarakeh J.I., Dehpour A.R. Morphine is protective against doxorubicin-induced cardiotoxicity in rat. Toxicology 2008, 243:96-104.
33. Kleindienst N., Greil W. Lithium in the long-term treatment of bipolar disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2003, 253:120-125.
34. Larsen R.L., Jakacki R.I., Vetter V.L., Meadows A.T., Silber J.H., Barber G. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am. J. Cardiol. 1992, 70:73-77.
35. Lenox R.H. Molecular basis of lithium action: integration of lithium-responsive signaling and gene expression networks. Mol. Psychiatry 2003, 8:135-144.
36. LippeIt P. Participationofendothelium-derivednitricoxide but not prostacyclin in the gastric mucosal hyperaemia due to acid back-diffusion. Br. J. Pharmacol. 1992, 105:708-714.
37. Lipshultz S.E., Rifai N., Sallan S.E., Lipsitz S.R., Dalton V., Sacks D.B., Ottlinger M.E. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997, 96:2641-2648.
38. Mair J., Apple F. Progress in myocardial damage detection: new biochemical markers for clinicians. Crit. Rev. Clin. Lab. Sci. 1997, 34:1-66.
39. Mair J., Artner-Dworzak E., Lechleitner P., Smidt J., Wagner I., Dienstl F., Puschendorf B. Cardiac troponin T in diagnosis of acute myocardial infarction. Clin. Chem. 1991, 37:845-852.
40. Manji H.K. G proteins: implications for psychiatry. Am. Psychiatric Assoc. 1992, 149:746-760.
41. Mozaffari M.S., Schaffer S.W. Effect of pressure overload on cardioprotection of mitochondrial KATP channels and GSK-3ß: interaction with the MPT pore. Am. J. Hypertens. 2008, 21:570-575.
42. Nahorski S.R., Regan C.I., Challiss R.A.J. Lithium and the phosphoinositide cycle: an example of uncompetitive inhibition and its pharmacological consequences. Trends Pharmacol. Sci. 1991, 12:297-303.
43. Nejadkey F., Nahavandi A., Dehpour A.R., Mani A.R. Role of nitric oxide in the gastroprotective effect of lithium. Pathophisiology 2006, 13:85-89.
44. Nousiainen T., Vanninen E., Rantala A., Jantunen E., Hartikainen J. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. J. Intern. Med. 1999, 245:359-364.
45. Rossi F., Filippelli W., Russo S., Filippelli A., Berrino L. Cardiotoxicity of doxorubicin: effects of drugs inhibiting the release of vasoactive substances. Pharmacol. Toxicol. 1994, 75:99-107.
46. Sartori C., Lepori M., Scherrer U. Interaction between nitric oxide and the cholinergic and sympathetic nervous system in cardiovascular control in humans. Pharmacol. Ther. 2005, 106:209-220.
47. Shaldubina A., Agam G., Belmaker R.H. The mechanism of lithium action: state of the art, ten years later. Prog. Neuro-Psychopharmacolog. Biol. Psychiatry 2001, 25:855-866.
48. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Eng. J. Med. 1998, 339:900-905.
49. Souza F.G., Goodwin G.M. Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. Br. J. Psychiatry 1991, 158:666-675.
50. Van Acker S., Kramer K., Voest E.E., Grimbergen J.A., Zhang J., van der Vijgh W.J.F., Bast A. Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. Cancer Chemother. Pharmacol. 1996, 38:95-101.
51. Villani F., Galimberti M., Monti E., Cova D., Lanza E., Rozza-Dionigi A., Favalli L., Poggi P. Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat. Toxicol. Appl. Pharmacol. 1990, 102:292-299.
52. Yoshikawa T., Handa S., Suzuki M., Nagami K. Abnormalities in sympathoneuronal regulation are localized to failing myocardium in rabbit heart. J. Am. Coll. Cardiol. 1994, 24:210-215.